Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDA with DHA-PPQ and Primaquine for Malaria in Senegal
NCT04864444Completed
- Sponsor
- University of California, San Francisco
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of dihydroartemisinin + piperaquine and primaquine in malaria (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Village-level confirmed incidence of malaria at 1 year. Started Jun 2021; status: completed.
02
Drugs
dihydroartemisinin + piperaquineprimaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04864444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864444.